Abstract
Impaired exercise capacity is the key symptom of heart failure (HF) and is associated with reduced quality of life and higher mortality rates. Unfortunately, current therapies, although generally lifesaving, have only small or marginal effects on exercise capacity. Specific strategies to alleviate exercise intolerance may improve quality of life, while possibly improving prognosis as well. There is overwhelming evidence that physical exercise improves performance in cardiac and skeletal muscles in health and disease. Unravelling the mechanistic underpinnings of exercise-induced improvements in muscle function could provide targets that will allow us to boost exercise performance in HF. With the current review we discuss: (i) recently discovered signalling pathways that govern physiological muscle growth as well as mitochondrial quality control mechanisms that underlie metabolic adaptations to exercise; (ii) the mechanistic underpinnings of exercise intolerance in HF and the benefits of exercise in HF patients on molecular, functional and prognostic levels; and (iii) potential molecular therapeutics to improve exercise performance in HF. We propose that novel molecular therapies to boost adaptive muscle growth and mitochondrial quality control in HF should always be combined with some form of exercise training.
Original language | English |
---|---|
Pages (from-to) | 287-298 |
Number of pages | 12 |
Journal | European Journal of Heart Failure |
Volume | 24 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2022 |
Externally published | Yes |
Bibliographical note
Funding Information:Dr. Westenbrink is supported by the Netherlands Organisation for Scientific Research (NWO VENI, grant 016.176.147) and the Netherlands Heart Foundation Senior Clinical Scientist Grant (2019T064) and CVON DOUBLE DOSE (grant 2020-8005). Dr. de Boer is supported by the Netherlands Heart Foundation (CVON DOUBLE DOSE, grant 2020-8005, CVON SHE-PREDICTS-HF, grant 2017-21, and CVON RED-CVD, grant 2017-11) and the European Research Council (ERC CoG 818 715, SECRETE-HF). Conflict of interest: The UMCG, which employs Nijholt, Sánchez-Aguilera, Voorrips, de Boer, and Westenbrink, has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. Dr. de Boer reports having received speaker fees from Abbott, AstraZeneca, Bayer, Novartis and Roche.
Funding Information:
Dr. Westenbrink is supported by the Netherlands Organisation for Scientific Research (NWO VENI, grant 016.176.147) and the Netherlands Heart Foundation Senior Clinical Scientist Grant (2019T064) and CVON DOUBLE DOSE (grant 2020‐8005). Dr. de Boer is supported by the Netherlands Heart Foundation (CVON DOUBLE DOSE, grant 2020‐8005, CVON SHE‐PREDICTS‐HF, grant 2017‐21, and CVON RED‐CVD, grant 2017‐11) and the European Research Council (ERC CoG 818 715, SECRETE‐HF).
Publisher Copyright:
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.